Claims for Patent: 10,519,252

Summary for Patent: 10,519,252

Title:	Aqueous iron carbohydrate complexes, their production and medicaments containing them
Abstract:	Water soluble Iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions.
Inventor(s):	Geisser; Peter (St. Gallen, CH), Philipp; Erik (Arbon, CH), Richle; Walter (Gossau, CH)
Assignee:	VIFOR (INTERNATIONAL) AG. (St. Gallen, CH)
Application Number:	13/835,400
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,519,252
Patent Claims:	1. An iron (III) carboxymaltodextrin complex wherein said iron (III) carboxymaltodextrin complex comprises polynuclear iron (III)-hydroxide 4(R)-(poly-(1.fwdarw.4)-O-.alpha.-D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-- tetrahydroxy-hexanoate and has a weight average molecular weight in the range of from 80 kDa to 400 kDa, and wherein said 4(R)-(poly-(1.fwdarw.4)-O-.alpha.-D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-- tetrahydroxy-hexanoate is derived from the oxidation of maltodextrin, wherein when one maltodextrin is applied its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrins contained in the mixture lies between 2 and 40. 2. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight in the range of from 80 kDa to 350 kDa. 3. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight in the range of from 80 kDa to 300 kDa. 4. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight in the range of from 118 kDa to 271 kDa. 5. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 271,000 Da. 6. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 141,000 Da. 7. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 140,000 Da. 8. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 189,000 Da. 9. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 118,000 Da. 10. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 178,000 Da. 11. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 137,000 Da. 12. The iron (III) carboxymaltodextrin complex of claim 1, having a weight average molecular weight of 170,000 Da. 13. A medicament comprising the iron (III) carboxymaltodextrin complex of claim 1 and a pharmaceutically acceptable carrier, excipient, or additive. 14. The medicament of claim 13, wherein said medicament is an aqueous solution. 15. The medicament of claim 14, wherein said aqueous solution is a brine solution. 16. The medicament of claim 14, wherein said iron (III) carboxymaltodextrin complex is present in said aqueous solution in an amount of from 1% to 20% by weight, based on the total weight of the aqueous solution. 17. The medicament of claim 14, wherein said iron (III) carboxymaltodextrin complex is present in said aqueous solution in an amount of 5% by weight, based on the total weight of the aqueous solution. 18. A method for treating an iron deficiency condition comprising the step of administering to a subject in need thereof a pharmaceutically effective amount of the medicament of claim 13. 19. The method of claim 18, wherein said iron deficiency condition is iron deficiency anaemia. 20. The method of claim 18, wherein said medicament is administered parenterally or orally. 21. The method of claim 18, wherein said medicament is administered intravenously or intramuscularly. 22. The method of claim 18, wherein said medicament is administered via injection. 23. The method of claim 18, wherein said medicament is administered via infusion. 24. The method of claim 18, wherein said medicament is administered in the form of a single dose. 25. The method of claim 24, wherein said single dose comprises from 500 to 1000 mg of iron. 26. The method of claim 25, wherein said single dose is applied during the course of one hour.